



The COVID-19 Pandemic: Insights and Implications for Insurers

Hosted by the International Insurance Society
and The Institutes

Daniel Zimmerman, M.D.

Julianne Callaway

Tim Rozar

12 May 2020

Agenda

Opening Remarks

Michael J. Morrissey, President and Chief Executive Officer, International Insurance Society (IIS)

The Medical View

Daniel Zimmerman, M.D., Senior Vice President and Chief Medical Director, Global Support Team

Research Highlights

Julianne Callaway, Vice President and Actuary, Strategic Research

A Look to the Future

Tim Rozar, Senior Vice President, Chief of Staff to the CEO

Q&A

Michael J. Morrissey, President and Chief Executive Officer, International Insurance Society (IIS)



The Medical View


Daniel Zimmerman, M.D.

*Senior Vice President and Chief Medical Director,
Global Support Team*



The Medical View

- Epidemiology and Trends
- Prevention
- Clinical Manifestations
- Treatment
- Recovery and Immunity




Epidemiology and Trends

Terminology

SARS-CoV-2 – the name of the virus

COVID-19 – the name of the disease caused by the virus

- Impact of social distancing
 - Differing strategies: Sweden
- Opening-up strategies
 - Testing and contact tracing
 - “Suppress and lift”
 - Mobile phone apps



Prevention

- Masks and face coverings
- Social distancing
- BCG vaccine – protective?

Coalition for Epidemic Preparedness Innovation

- Created in 2017
- Stimulate and accelerate the development of vaccines against emerging infectious diseases and enable access to these vaccines for people during outbreaks
- Moving quickly to rapidly develop vaccines against COVID-19
- www.cepi.net

Vaccine update

- Leveraging prior research
- Accelerating the timeline – collaboration
- Many candidate vaccines and strategies*
- Safety and efficacy
- Long-term protection needed
- Older individuals – immune response
- Mass production
- Acceptance of vaccine by people?

*virus, viral vector, nucleic acid, protein-based

Clinical Manifestations


Risk factors for serious disease

- Age 65 and older
- People in nursing home or LTC facility
- Chronic lung disease
- Serious heart conditions
- Immunocompromised
- Certain cancers
- Obesity, BMI >30
- Diabetes
- Chronic kidney disease
- Liver disease

Unexpected consequences

- Kidney failure requiring dialysis
- Cardiac “injury”
- Neurological symptoms including stroke
- Abnormal clotting of blood
- Liver damage
- Children with emerging inflammatory condition

Rates of hospitalization increase with age



CDC – adapted from U.S. Government Image – MMWR 17 Apr 20

Treatment

Remdesivir
Convalescent plasma
Other antivirals
Azithromycin
Monoclonal/polyclonal antibodies
Hydroxychloroquine and
chloroquine (antimalarials)
Stem cells and other cells

- Use caution when reviewing and interpreting results of clinical trials

Longer Life Foundation

RGA collaboration with Washington University
in St. Louis School of Medicine

Cutting-edge research

www.longerlife.org

LinkedIn/Twitter

Novel technologies being employed: cloning of SARS-CoV-2 proteins in human cells to identify how they interact to identify druggable targets

Recovery and Immunity

A very complex issue...

More questions than answers!

- What is the correlation between resolution of symptoms and length of viral shedding?
- Could there be long-term health consequences in those who recover from COVID-19?
- Are antibodies protective?
- What if someone has a low or undetectable level of antibody?
- Is there a risk of reinfection?
- What is the quality of antibody tests now available?
- Will it be possible to issue “immunity certificates”?

RGA


Research Highlights

Julianne Callaway, FSA, ACAS, MAAA
Vice President and Actuary, Strategic Research



Challenges

Evolving landscape of data and expert guidance




Procedural Changes

- Limiting tests to hospitals
- Counting probable cases and deaths, not just confirmed



Under-/Overcounting

- Only counting hospitalized COVID-19 deaths
- Dying from another cause while also having COVID-19



Government Interventions

- Societal changes impact mortality experience
- These changes impact expert model projections

Research Approach



Wide-Ranging Expertise


- Epidemiological
- Actuarial
- Advanced analytics



Data


- Government data
- Academic institutions
- Scientific literature

COVID-19 Mortality Rate by Age for Select Countries



- The COVID-19 mortality rate is much higher (roughly 20 times greater) for people over age 60 compared those under age 60
- The age shape of COVID-19 mortality experience is very different from that of previous pandemics


All-Cause and COVID-19 Mortality Differences by Gender



- The COVID-19 Gender Mortality Ratio (GMR) is generally higher than the all-cause GMR, suggesting that there is a bigger sex differential in COVID-19 than in all-cause mortality
- Possible explanations for worse male COVID-19 experience:
 - Lifestyle
 - Behavioral
 - Biological


COVID-19 Gender Mortality Ratios by Age Group

COVID-19 Gender Mortality Ratios, Age 60+
(Male Mortality Rate divided by Female Mortality Rate)




- Male COVID-19 mortality experience is typically about twice the COVID-19 mortality experience of females
- The differences are more pronounced at ages 60-69 than at older ages

U.S. COVID-19 Hospitalizations with Underlying Medical Conditions



- According to the U.S. CDC, the majority of COVID-19-related hospitalized patients have an underlying medical condition
- Nearly 90% of COVID-19-related hospital admissions in the U.S. involve co-morbidities

COVID-19 Experience of Diamond Princess Passengers by Age Group



The *Diamond Princess* cruise ship offers a rare opportunity to understand features of the virus that are hard to investigate in the wider population

- Represents experience from affluent, generally healthy people
- All passengers were tested, allowing for analysis of:
 - Asymptomatic prevalence
 - Estimates of Infection Fatality Rates
- Over half of the passengers were aged 60+ and this was the only age group that experienced deaths; many who died had underlying health conditions

Data Sources

Country	Source	Date
Italy	<u>Epicentro - Higher Institute of Health</u>	4.23.2020
Netherlands	<u>National Institute for Public Health and the Environment</u>	4.29.2020
South Korea	<u>Korea Center for Disease Control and Prevention</u>	4.29.2020
Spain	<u>Ministry of Health, Consumption and Social Welfare</u>	4.29.2020
United Kingdom	<u>Office for National Statistics</u>	4.17.2020
Belgium	<u>Belgian Scientific Institute of Public Health, Sciensano</u>	4.28.2020
U.S.	<u>Centers for Disease Control and Prevention</u>	4.25.2020
Diamond Princess	<u>https://cmmid.github.io/topics/covid19/diamond_cruise_cfr_estimates.html</u>	3.23.2020



A Look to the Future

Tim Rozar, FSA, CERA, MAAA
Senior Vice President, Chief of Staff to the CEO




Looking Back to Look Forward

If you've seen one, you've seen...one

- Limited data points to analyze
- Every situation unique
 - Epidemiology
 - External influences
 - Response capabilities
- Must avoid complacency or overconfidence

HISTORY OF PANDEMICS




<https://www.visualcapitalist.com/history-of-pandemics-deadliest/>

Primary Determinants of Impact

Behavioral



- Mitigation actions
- Consumer/intermediary trends
- Government, central bank, and regulatory actions
- Adverse selection



Medical



- Disease characteristics
- Healthcare delivery capacity
- Therapeutics
- Secondary ripple effects (often surprising, e.g. motor vehicle accidents)

Financial



- Impact of mitigation
- Balance sheet resilience
- Macro-economic conditions

Potential Long-Term Impact on Insurance Industry

More questions than answers...

Medical

- Long-term impact on COVID-19 survivors
- Mortality improvement trends
 - Short-term vs. longer-term
 - Research and medical advances
 - Behavioral changes
- Evolution of risk assessment
- Investment in expertise

Behavioral

- Demand dynamics
 - Perception of value of insurance/reinsurance
 - Distribution channels
 - Risk transfer by companies
- Optionality, adverse selection, and fraud
- Regulatory/ratings
 - Coverage requirements
 - Extended grace periods
 - Capital ratios
- Trust
 - Models, financial strength, social responsibility

Financial

- Balance sheet impacts
 - Asset portfolios
 - Recalibration of capital models
- Strategic business analysis
- Impact of stimulus efforts
 - Austerity, interest rates, inflation
- Consumer
 - Unemployment
 - Disability
 - Disposable income

Q & A

Additional Questions

rgare.com/webinar-contacts

RGA

©2020 RGA. All rights reserved.

No part of this publication may be reproduced in any form without the prior permission of RGA.

The information in this publication is for the exclusive, internal use of the recipient and may not be relied upon by any other party other than the recipient and its affiliates, or published, quoted or disseminated to any party other than the recipient without the prior written consent of RGA.